Evidence map›Paper›PMID 41639524›Full record

ArticleScience China. Life sciences2026

USP7 protects histone H1.2 from proteasome-mediated degradation to facilitate DNA repair and pancreatic neuroendocrine neoplasms progression.

Mujie Ye, Lin Xu, Ping Yu, Jialing Pan, Xiaoting Shi, Bingyan Xue, Na He, Ping Hu, Min Liu, Xintong Lu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mujie Ye *Department of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China.
Lin Xu *Department of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China.
Ping Yu *Department of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China.
Jialing Pan *Department of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China.
Xiaoting ShiDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China.
Bingyan XueDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China.
Na HeDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China.
Ping HuDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China.
Min LiuDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China.
Xintong LuDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China.
Yuemei XuDepartment of Pathology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China. yuemeixu2015@163.com.
Yanling XuDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China. yanlingxu@njmu.edu.cn.
Qiyun TangDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, 210029, China. qytang@njmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ubiquitin-specific protease 7 (USP7), a deubiquitinase, is involved in tumor progression. However, its roles in pancreatic neuroendocrine neoplasms (pNENs) remain unclear. The main objective of this study was therefore to investigate the molecular mechanism of how USP7 promoted pNEN progression. Proteomics and ubiquitin-omics were used to identify the substrates for USP7. We investigated the roles of USP7 and histone H1.2 in DNA repair in pNEN cells using comet assays and γ-H2AX immunofluorescence. The synergistic effects of cisplatin and the USP7 inhibitor, P005091, were evaluated using CCK-8, colony formation, and EdU assays. Western blot analysis was conducted to characterize the PI3K/AKT/mTOR signaling pathway. In vivo, the efficacy of the combination therapy was tested in xenograft models. The results showed a significant increase in USP7 levels in the tissues and cells of pNENs. Furthermore, USP7 was found to promote the proliferation, migration, and invasion of pNENs both in vitro and in vivo. Mechanistically, USP7 facilitated DNA repair through its interaction with histone H1.2 and the activation of the PI3K/AKT/mTOR pathway. The combination of cisplatin and P005091, a USP7 inhibitor, synergistically inhibited tumor growth and DNA repair in both in vitro and in vivo models, without exhibiting significant toxicity. In conclusion, USP7 was a key regulator of DNA repair in pNENs. The combination of cisplatin and P005091 therefore holds promise as a therapeutic strategy for pNENs.

Indexed as

DNA RepairHistonesNeuroendocrine TumorsPancreatic NeoplasmsProteasome Endopeptidase ComplexUbiquitin-Specific Peptidase 7AnimalsCell Line, TumorCell MovementCell ProliferationCisplatinDisease ProgressionHumansMiceMice, NudePhosphatidylinositol 3-KinasesCisplatinHistonesPhosphatidylinositol 3-KinasesProteasome Endopeptidase ComplexProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesUbiquitin-Specific Peptidase 7USP7 protein, humancisplatinDNA repairhistone H1.2pancreatic neuroendocrine neoplasmsUSP7

Identifiers

PMID41639524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.